Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
P/S ratio for Intercept Pharmaceuticals, Inc. (ICPT)
P/S ratio as of 2022: 1.46
According to Intercept Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.46. At the end of 2021 the company had a P/S ratio of 1.43.
P/S ratio history for Intercept Pharmaceuticals, Inc. from 2010 to 2022
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2022 | 1.46 |
| 2021 | 1.43 |
| 2020 | 2.60 |
| 2019 | 15.57 |
| 2018 | 15.96 |
| 2017 | 11.18 |
| 2016 | 107.40 |
| 2015 | 1272.00 |
| 2014 | 1861.25 |
| 2013 | 759.12 |
| 2012 | 87.96 |
| 2011 | 35.78 |
| 2010 | 0.00 |